The BTK Revolution: How BTK Inhibitor Drugs Are Changing the Treatment Landscape for Mantle Cell Lymphoma
The introduction of BTK inhibitor drugs has been one of the most significant advances in the treatment of mantle cell lymphoma (MCL). These agents, which target Bruton's tyrosine kinase (BTK), a critical enzyme in B-cell signaling, have reshaped the therapeutic landscape, offering a highly effective and well-tolerated alternative to traditional chemotherapy. The global market for MCL...
0 Comments 0 Shares 56 Views 0 Reviews